CeriBell, Inc. (CBLL)
| Market Cap | 765.02M +37.7% |
| Revenue (ttm) | 89.06M +36.1% |
| Net Income | -53.41M |
| EPS | -1.46 |
| Shares Out | 37.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307,256 |
| Open | 20.37 |
| Previous Close | 20.38 |
| Day's Range | 19.82 - 20.55 |
| 52-Week Range | 10.85 - 24.33 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 23.20 (+14.91%) |
| Earnings Date | May 11, 2026 |
About CBLL
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote acc... [Read more]
Financial Performance
In 2025, CeriBell's revenue was $89.06 million, an increase of 36.09% compared to the previous year's $65.44 million. Losses were -$53.41 million, 32.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price target is $23.2, which is an increase of 14.91% from the latest price.
News
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...
Ceribell receives 510(k) premarket notification for brain monitor headband
The FDA posted a 510(k) premarket notification notice for the Ceribell (CBLL) Brain Monitor Headband with a decision date of April 3. The FDA decision was “substantially equivalent,” according to
CeriBell Transcript: TD Cowen 46th Annual Health Care Conference
Consistent outperformance and strong 2026 growth guidance are supported by expanded sales force and new product launches in neonatal, pediatric, and delirium indications. Operational efficiencies maintain high margins, while unique FDA clearances and AI capabilities differentiate from competitors.
CeriBell Transcript: 47th Annual Raymond James Institutional Investor Conference
A novel rapid EEG platform with AI-driven seizure detection achieved $89M in 2025 revenue and 36% growth, expanding its market with pediatric, neonate, and delirium indications. With only 3% U.S. market penetration, the company is focused on deeper hospital adoption, new indications, and leveraging its platform for future growth.
Ceribell price target lowered to $28 from $30 at Canaccord
Canaccord lowered the firm’s price target on Ceribell (CBLL) to $28 from $30 and keeps a Buy rating on the shares. The firm said they reported a solid beat for
Ceribell reports Q4 EPS (36c), consensus (41c)
Reports Q4 revenue $24.78M, consensus $23.95M. “2025 was a milestone year for Ceribell (CBLL),” said co-founder and CEO Jane Chao. “We accelerated adoption across new and existing accounts, broadened ...
Ceribell sees FY26 revenue $111M-$115M, consensus $112.67M
The company said, “Ceribell (CBLL) expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29%
CeriBell Earnings Call Transcript: Q4 2025
Delivered 36% revenue growth in 2025, expanded TAM to $3.5B, and achieved key FDA clearances for new indications. 2026 guidance calls for 25–29% revenue growth, with new product launches and deeper account penetration expected to drive upside.
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in Upcoming March Investor Conferences
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ceribell showcased strong growth, expanding its neuromonitoring platform's reach with FDA clearances for pediatric, neonate, and delirium detection, increasing its TAM to $3.5B. The company plans to leverage its expanded sales force and new product launches in 2026, aiming for deeper market penetration and operational efficiency.
Ceribell receives FDA breakthrough device designation for LVO SD monitor
CeriBell (CBLL) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its Large Vessel Occlusion stroke detection monitor for patients in the hospital se...
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell price target raised to $30 from $29 at Canaccord
Canaccord raised the firm’s price target on Ceribell (CBLL) to $30 from $29 and keeps a Buy rating on the shares. The firm said they continue to be bullish on
Ceribell price target raised to $29 from $20 at TD Cowen
TD Cowen raised the firm’s price target on Ceribell (CBLL) to $29 from $20 and keeps a Buy rating on the shares after the company announced that it has received
Ceribell receives FDA 510k clearance for delirium screening, monitoring device
CeriBell (CBLL) announced that the U.S. Food and Drug Administration, FDA, has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium scree...
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell Transcript: Piper Sandler 37th Annual Healthcare Conference
A novel neuro monitoring platform with AI-driven seizure detection is driving rapid growth, improved clinical outcomes, and expanding market reach in acute care. The company is focused on US expansion, new indications, and leveraging its first-mover advantage.
Ceribell management to meet virtually with BTIG
Virtual Meeting to be held on December 9 hosted by BTIG.
Ceribell receives FDA 510(k) clearance for Clarity algorithm
CeriBell (CBLL) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its next-generation Clarity algorithm to detect electrographic seizures in newborns pre-term and o...
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures Becomes th...
CeriBell Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
A novel EEG monitoring system is driving rapid growth, with strong financials, expanding hospital adoption, and a robust sales pipeline. Strategic manufacturing shifts and a defensible AI-driven algorithm support long-term profitability and market leadership.